Supporting Respiratory Treatments
The system plays a critical role in the production of DPI devices used to treat chronic respiratory conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD). For over 20 years, Mpac Lambert has collaborated with dry powder inhaler manufacturers to design machines that meet the production needs of fast-evolving treatments for these respiratory diseases.
Precision Engineering for Difficult Formulations
Effective treatment often relies on API combinations using excipient-blended powders that are difficult to process but enable improved delivery of drugs to the lungs. Mpac Lambert's forming, filling and sealing automation is specifically designed to process these combinations efficiently, helping pharma producers keep DPIs available to users worldwide. Engineered with precision and safety in mind, the DPI Blister Filling Machine ensures accurate micro-dosing of Active Pharmaceutical Ingredients (APIs), eliminating contamination risk and maximizing dose integrity.
Key Features Of The DPI Blister Filling Machine
- High-Precision Dosing: Direct powder dosing into pre-formed blister pockets ensures consistent drug delivery and eliminates the need for secondary cleaning.
- Contamination-Free Sealing: The innovative rotary blade filling system ensures clean strip surfaces, enabling perfect seals and preserving medication efficacy.
- Full Line Integration: Incorporates forming, filling, and sealing stations with robust tension and alignment controls, CE, UKCA, UL compliance, and GAMP support.
- Scalable And Flexible: Supports multiple strip formats (7 to 60 doses), various powder formulations, and a range of throughput demands - from R&D to commercial production.
Global Reach and Trusted Expertise
Mpac Lambert’s automation forms part of DPI production lines across the globe, from R&D validation solutions to commercial production lines. Its scalable automation grows with businesses. “At least one strip in the most widely used DPI devices on the market today is produced using our system,” said a spokesperson for Mpac Lambert. “This reflects not just our technological innovation, but also the trust global pharmaceutical leaders place in our automation expertise.”
